“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Improves Quality of Life in Psoriasis: Results from a Phase 2 Study”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S12. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/739.